As 100 Percent Fed Up noted, the southern Indian state of Kerala reportedly implemented containment zones that went into a “lockdown-like situation” due to a Nipah virus outbreak.

According to health officials, Nipah virus has a fatality rate between 40% and 75%.

The UK Health Security Agency (UKHSA) said it was ‘closely monitoring‘ the situation.

Health Officials on Alert About Pathogen With Up to 75% Fatality Rate

Two individuals in India reportedly died due to the outbreak and authorities tested hundreds more for “potential contacts” for the “brain-damaging virus.”

The containment zones went into a total shutdown similar to the COVID-19 lockdowns.

According to reports, close contacts of the infected individuals are being tracked and in isolation.


India Today reported:

These two deaths occurred at a private hospital in Kozhikode. Four people under treatment are relatives of the second deceased person. Their samples were sent for testing. Two tested positive, including a 9-year-old child and a 24-year-old relative. The 9-year-old child of the deceased is in ventilation at a private hospital.

A high-level meeting was chaired by Kerala Health Minister Veena George to review the situation. Kozhikode has experienced two previous Nipah virus outbreaks, one in 2018 and another in 2021. During the first outbreak in 2018, 23 cases were identified, with 17 people succumbing to this zoonotic virus.

An official from Kerala’s health ministry said that the virus was transmitted to humans through direct contact with the bodily fluids of infected bats, pigs, or other people.

On Wednesday, a lockdown-like situation prevailed in the containment zones after the government issued a fresh set of restrictions to prevent the spread of the virus.

“In areas declared as containment zones, social distancing and the use of masks and sanitisers is mandatory,” the outlet noted.

Could Nipah virus be the next ‘plandemic’ engineered by the global elite?

Are they using the threat of a ‘virus’ with a much higher fatality rate to frighten the world back into lockdowns?

It’s unclear at the moment.


However, we know Nipah virus has been a talking point for globalist institutions in recent years.

The World Economic Forum made a passing mention of Nipah virus in March 2020:

Increases in deforestation spur new outbreaks; loss of tree cover has been rising steadily over the past 17 years, and 31% of outbreaks of new and emerging diseases, such as the Nipah virus, Zika and Ebola, are linked to deforestation.

Gavi, the Vaccine Alliance questioned in March 2021 if Nipah virus was the next pandemic:

Disease: Nipah

Where is it circulating? South-East Asia, with outbreaks in Bangladesh, India, Malaysia and Singapore

Pandemic threat: High. In many South-East Asian countries, the possibilities for the virus to spill over from bats to other animals and to humans are endless. Fruit bats live in trees in close proximity to markets, places of worship, schools and tourist spots. Bat guano is used as fertiliser in fields too, meaning that farmers and agricultural workers are potentially in frequent contact with the virus. In the ‘Nipah belt’ on the Bangladesh-India border, outbreaks happen regularly, and recent research indicates that bats across Bangladesh harbour the virus, suggesting undetected outbreaks could be occurring. Yet the awareness of where Nipah comes from is extremely low, even where outbreaks occur; a survey from Cambodia indicated that 60% of people didn’t know that bats, or flying foxes as they are sometimes called, spread the virus. Still as 60% of the world’s population lives in the region where Nipah originated and deforestation and environmental change continue to bring humans, livestock and wildlife closer, the risk of spill-over events grows. The disease is also so deadly that many governments classify it as a bioterrorism threat and limit the laboratories that are allowed to culture and study it.

How is it spread? The Nipah virus lives among the Pteropodidae family of fruit bats. It can spread to humans, often through eating or drinking products contaminated by fruit bat droppings. For instance, the bats occupy date trees and consumption of date products can lead to infection. It also easily infects a wide variety of animals – an outbreak in farmers in Malaysia in 1998 originated in pigs, who had previously been infected by bats. The disease can also spread from human to human, and the theory is that the virus can travel in respiratory secretions and saliva, such as that expelled by coughing. Most infections seem to have come from infected patients who had breathing problems, which supports this theory.

Case fatality rate: Between 40% and 75%.

Incubation period: On average 5-14 days, but in some extreme cases up to 45 days, which can mean a lot of time for an infected person to unknowingly infect others.

Symptoms: The virus can cause acute respiratory infection and encephalitis (inflammation of the brain) that can lead to a coma or death. Symptoms include fever, headaches, myalgia (muscle pain), vomiting and sore throat. This can be followed by dizziness, drowsiness and altered consciousness. One in five people who survive can develop seizure disorders and experience personality changes.

Diagnosis: The main tests used are real-time polymerase chain reaction (RT-PCR) from bodily fluids and antibody detection via enzyme-linked immunosorbent assay (ELISA). Other tests used include PCR, and virus isolation by cell culture. These tests are often not well suited for use in remote and rural settings, where most outbreaks occur and where containment capabilities are lacking.

Are there vaccines or treatments, or ongoing R&D? There are no existing vaccines or treatments, but a phase 1 clinical study of a Nipah virus vaccine candidate (HeV-sG-V) started in February 2020 and is expected to be completed in September 2021. The Coalition for Epidemic Preparedness Innovations (CEPI) invested US$ 25 million in 2018 to kickstart an initial safety study that is run by Auro Vaccines LLC and led by PATH, and conducted at the Cincinnati Children’s Hospital Medical Center in Cincinnati, USA. The vaccine will be tested in healthy adults aged 18-49 years to assess the safety and how well the vaccine triggers an immune response.

“Here’s what the terrifying Nipah virus can teach us about the spread of COVID-19,” the WEF posted in November 2020.

The WEF wrote:

Nipah virus may have a lot to teach us about dealing with COVID-19, Stephen Luby says.

Discovered 20 years ago, Nipah virus can spread from bats or pigs to humans. Found only in South and South East Asia so far, it kills nearly three-quarters of the people it infects.

There is no vaccine for it and no cure, and it has many strains capable of spreading from person to person, increasing the chances of a strain emerging with the ability to rapidly spread beyond the region.

Luby, a professor of infectious diseases at Stanford University, has done extensive research on Nipah and the bats that spread it in Bangladesh through their contamination of fresh date palm sap, a popular drink in the country.

Luby cowrote a new study in the Proceedings of the National Academy of Sciences that examines the role of Pteropus medius bats and human-caused environmental factors in Nipah’s spread. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, edited the study.


In 2022, National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial for an experimental mRNA Nipah virus vaccine manufactured by Moderna.

From the NIH:

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine is manufactured by Moderna, Inc., Cambridge, Massachusetts, and was developed in collaboration with NIAID’s Vaccine Research Center. It is based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines. NIAID is sponsoring the Phase 1 clinical study, which is being conducted at the NIH Clinical Center in Bethesda, Maryland.

Nipah virus infection is a zoonotic disease, meaning that it is spread between animals and people. Fruit bats are the natural host for the virus. The first known Nipah outbreak occurred in 1998 in Malaysia and Singapore and resulted in 265 human cases and 105 deaths, and caused significant economic damage to the swine industry there. Since 1999, outbreaks have occurred annually in Asia, primarily in Bangladesh and India. The virus can cause mild-to-severe disease rapidly progressing from respiratory infection symptoms to encephalitis (brain swelling) leading to coma or death. An estimated 40% to 75% of people infected with Nipah virus die. Although most cases are transmitted via animals, person-to-person transmission can occur. Currently, there is no licensed vaccine or treatment for Nipah virus infection.

“Nipah virus poses a considerable pandemic threat because it mutates relatively easily, causes disease in a wide range of mammals, can transmit from person-to-person, and kills a large percentage of the people it infects,” said NIAID Director Anthony S. Fauci, M.D. “The need for a preventive Nipah virus vaccine is significant.”

NIAID’s Pandemic Preparedness Plan, published earlier this year, established a framework to study viruses of pandemic potential and prioritize research on prototype pathogens, such as Nipah virus. This is the first clinical trial using the prototype pathogen approach since the plan’s publication.

The experimental mRNA-1215 Nipah virus vaccine will be tested in a dose-escalation clinical trial to evaluate its safety, tolerability, and ability to generate an immune response in 40 healthy adults ages 18 to 60 years. Specifically, four groups of 10 participants each will receive two doses of the investigational vaccine via injection in the shoulder muscle four or 12 weeks apart. Group one (10 participants) will receive two 25-microgram (mcg) injections; group two will receive two 50-mcg injections; and group three will receive two 100-mcg injections, each four weeks apart. The vaccine dose for the fourth group of participants will be determined based on an interim analysis of the results from the three previous groups. The fourth group will receive two injections 12 weeks apart. Study participants will be evaluated through clinical observation and blood collection at specified times throughout the study and will be followed by clinical study staff through 52 weeks following their final vaccination.

Join The Conversation. Leave a Comment.

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.